Wisevoter
U.S.

Lumos Expands FebriDx to 97 WellStreet Clinics

The rapid fingerstick test will bring total participating WellStreet clinics to 141 across Ohio, Georgia and Michigan.

Updated on Nov. 9, 2026 in Asthma

Photograph of an empty clinic corridor with small unlabeled glass vials on a pale counter beside a window in soft daylight.
Lumos Diagnostics is expanding its FebriDx fingerstick test to 97 more WellStreet Urgent Care clinics, bringing participating sites to 141. AI Illustration. Upload story photo >

Live Poll

Would you trust a rapid test to help your doctor decide whether you need antibiotics?

Lumos Diagnostics is expanding its FebriDx test to 97 additional WellStreet Urgent Care locations, bringing WellStreet's participating clinics to 141. The test uses a fingerstick blood sample to help distinguish bacterial from non-bacterial infections.

Why it matters

The expansion increases the number of U.S. sites using FebriDx to 365 once implemented, giving patients with acute respiratory symptoms access to rapid infection differentiation at urgent care visits. Respiratory symptoms account for an estimated 70% to 80% of visits during cold and flu season.

The figures reflect company-reported deployment counts, with WellStreet operating more than 200 clinics and managing over 1 million acute respiratory infection presentations annually. Clinical outcome data from the expanded rollout has not been reported.

The players

Lumos Diagnostics

Lumos Diagnostics is the company that developed and markets the FebriDx rapid test for differentiating bacterial and non-bacterial infections.

WellStreet Urgent Care

WellStreet Urgent Care is the sixth-largest urgent care network in the United States, operating more than 200 clinics.

U.S. Food and Drug Administration

The U.S. Food and Drug Administration is the federal agency that granted FebriDx a CLIA waiver in March 2026, allowing its use in non-laboratory settings.

The details

Lumos began a single-site pilot with WellStreet in Atlanta, Georgia, in October 2025, and the FDA granted FebriDx a CLIA waiver in March 2026. Under WellStreet's clinical protocol, the test is offered to patients presenting with acute respiratory infection symptoms, with results available before the provider enters the examination room.

Timeline

  1. October 2025: Single-site FebriDx pilot began in Atlanta, Georgia.

  2. March 2026: FDA granted FebriDx a CLIA waiver.

  3. November 9, 2026: Expansion to 97 additional WellStreet locations announced.

  4. December 31, 2026: Target date for extending FebriDx to all WellStreet locations.

Market Context

The expansion follows the FDA's March 2026 CLIA waiver for FebriDx, which allowed the test to move from laboratory settings into urgent care clinics. The rollout pattern, from a single-site pilot to 141 WellStreet clinics, shows how a waived rapid test can scale through a single large provider network.

Patients visiting participating WellStreet clinics with respiratory symptoms may receive a fingerstick test that distinguishes bacterial from non-bacterial infection before seeing a provider. This may affect whether antibiotics are prescribed at the visit.

The takeaway

Respiratory symptoms make up a large share of urgent care visits during cold and flu season, so rapid tests that separate bacterial from viral causes could shape how these visits are managed. Patients with respiratory symptoms can ask whether a rapid test is available at their urgent care clinic.

What happens next

WellStreet and Lumos anticipate extending FebriDx testing across all WellStreet locations by December 31, 2026.

Further reading

Explore more on Asthma for context on respiratory illness diagnosis and treatment.

Source note: This article includes information reported by Proactiveinvestors NA.

Live Poll

Would you trust a rapid test to help your doctor decide whether you need antibiotics?